Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
R&D Roundup: Pharma gets in on the biotech boom
Roche insists Spark deal is still on, despite lacklustre take-up
Spark/Novartis eye gene therapy nears EU market – but at what price?
Biotech still pressing on with late stage trials
Spark shares tank after haemophilia gene therapy safety signal
Pfizer moves haemophilia gene therapy into phase 3
Ophthalmic Drugs Conference London
Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018
Voucher prices have fallen since their 2015 peak
Priority review voucher prices fall again after Spark’s $110m sale